Brainstorm Cell Therapeutics Inc.
BCLI
$1.00
$0.011.01%
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 106.39% | -7.76% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 76.59% | -8.82% | |||
| Operating Income | -76.59% | 8.82% | |||
| Income Before Tax | -81.24% | 12.61% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -81.24% | 12.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -81.24% | 12.61% | |||
| EBIT | -76.59% | 8.82% | |||
| EBITDA | -77.55% | 8.52% | |||
| EPS Basic | -81.22% | 12.44% | |||
| Normalized Basic EPS | -81.16% | 12.43% | |||
| EPS Diluted | -81.22% | 12.44% | |||
| Normalized Diluted EPS | -81.16% | 12.43% | |||
| Average Basic Shares Outstanding | 0.00% | -0.18% | |||
| Average Diluted Shares Outstanding | 0.00% | -0.18% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||